Who founded Glyphic Biotechnologies?

Glyphic Biotechnologies was founded by Joshua Yang, Daniel Estandian, Ed Boyden in 2021.

Who are Glyphic Biotechnologies's investors?

Glyphic Biotechnologies's investors include Artis Ventures, Black Flag, Civilization Ventures Management, Llc, FoundersX Ventures, LongeVC, Modi Ventures, OMX Ventures, Wing and 2 more.

How much funding has Glyphic Biotechnologies raised?

Glyphic Biotechnologies has disclosed $33.2M raised across 1 round.

Where is Glyphic Biotechnologies headquartered?

Glyphic Biotechnologies is headquartered in Berkeley, US.

Glyphic Biotechnologies

Berkeley, US · Founded 2021 · Delaware corporation · 10 known investors

glyphic.bio ↗

Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity. The platform serves research and therapeutic development in proteomics and drug discovery.

BiotechDeep Tech

Founders & leadership

Glyphic Biotechnologies was founded in 2021 by Joshua Yang, Daniel Estandian, and Ed Boyden.

Joshua YangFounder & CEO

Daniel EstandianFounder

Ed BoydenFounder

Board

Craig Asher in 𝕏Board MemberManaging Director at OMX Ventures

Jimmy YunBoard director

Investors · 10

Artis VenturesSan Francisco · $50K – $25M

Black FlagSan Diego · $100K – $1M

Civilization Ventures Management, LlcTiburon · $1M – $10M

FoundersX VenturesSilicon Valley

LongeVCWashington D.C.

Modi VenturesHouston

OMX VenturesLincolnshire

WingPalo Alto · $200K – $20M

Axial VCreportedSan Francisco · $100K – $5M

Cantos VenturesreportedSan Francisco · $400K – $1.5M

Reported raises · per SEC filings

Form D private placements

$33.2M disclosed across 1 round · 2024

▶$33.2MraisedFeb 2024 · 37 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Joshua YangExecutive Officer, Director
Craig AsherDirector
Jimmy YunDirector
Daniel EstandianExecutive Officer, Director

Offering amount: $52.9M
Amount sold: $33.2M
First sale: Feb 2024
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Genomeweb17 shared keywordsGenomeWeb's Research Funding section publishes news coverage of research grants and government funding trends in genetics, genomics, and molecular diagnostics. It is an industry news publication serving researchers and organizations in the life sciences.

Peptilogics7 shared keywordsPeptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections. Its lead candidate is in a pivotal Phase 2/3 trial and holds FDA Orphan Disease, Fast Track, and QIDP designations.

Macrogenics Inc7 shared keywordsMacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients. It advances a pipeline of product candidates using proprietary platforms for antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers.

Companies competing with Glyphic Biotechnologies for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2023	$408.9K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2023	$390.6K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2023	$359K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2022	$409.3K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Glyphic Biotechnologies do?: Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity. The platform serves research and therapeutic development in proteomics and drug discovery.
Who founded Glyphic Biotechnologies?: Glyphic Biotechnologies was founded by Joshua Yang, Daniel Estandian, Ed Boyden in 2021.
Who are Glyphic Biotechnologies's investors?: Glyphic Biotechnologies's investors include Artis Ventures, Black Flag, Civilization Ventures Management, Llc, FoundersX Ventures, LongeVC, Modi Ventures, OMX Ventures, Wing and 2 more.
How much funding has Glyphic Biotechnologies raised?: Glyphic Biotechnologies has disclosed $33.2M raised across 1 round.
Where is Glyphic Biotechnologies headquartered?: Glyphic Biotechnologies is headquartered in Berkeley, US.